Shanghai Haohai Biological Technology Balance Sheet Health
Financial Health criteria checks 5/6
Shanghai Haohai Biological Technology has a total shareholder equity of CN¥6.0B and total debt of CN¥423.7M, which brings its debt-to-equity ratio to 7%. Its total assets and total liabilities are CN¥7.2B and CN¥1.2B respectively. Shanghai Haohai Biological Technology's EBIT is CN¥404.8M making its interest coverage ratio -6.4. It has cash and short-term investments of CN¥2.7B.
Key information
7.0%
Debt to equity ratio
CN¥423.70m
Debt
| Interest coverage ratio | -6.4x |
| Cash | CN¥2.69b |
| Equity | CN¥6.03b |
| Total liabilities | CN¥1.21b |
| Total assets | CN¥7.25b |
Recent financial health updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Financial Position Analysis
Short Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its short term liabilities (CN¥861.5M).
Long Term Liabilities: 6826's short term assets (CN¥3.7B) exceed its long term liabilities (CN¥350.6M).
Debt to Equity History and Analysis
Debt Level: 6826 has more cash than its total debt.
Reducing Debt: 6826's debt to equity ratio has increased from 0.7% to 7% over the past 5 years.
Debt Coverage: 6826's debt is well covered by operating cash flow (159%).
Interest Coverage: 6826 earns more interest than it pays, so coverage of interest payments is not a concern.